Infections after CD34‐selected or unmanipulated autologous hematopoietic stem cell transplantation
暂无分享,去创建一个
[1] P. Mol,et al. Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures , 2004, Bone Marrow Transplantation.
[2] S. Grupp,et al. An unexpectedly high incidence of Epstein–Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma , 2004, Bone Marrow Transplantation.
[3] I. Majolino,et al. Hemopoietic Recovery and Infectious Complications in Breast Cancer and Multiple Myeloma after Autologous CD34+ Cell-Selected Peripheral Blood Progenitor Cell Transplantation , 2004, International journal of hematology.
[4] M. Mayes,et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] P. Moss,et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] G. Carcelain,et al. Evidence for naive T-cell repopulation despite thymus irradiation after autologous transplantation in adults with multiple myeloma: role of ex vivo CD34+ selection and age. , 2003, Blood.
[7] Dirk Hasenclever,et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.
[8] M. Boeckh,et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] H. Einsele,et al. Definitions of infectious diseases and complications after stem cell transplant , 2002 .
[10] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] A. Toor,et al. Infections during mobilizing chemotherapy and following autologous stem cell transplantation , 2001, Bone Marrow Transplantation.
[12] H. Rugo,et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Ueda,et al. CD34+-Selected Autologous Peripheral Blood Stem Cell Transplantation Conditioned With Total Body Irradiation for Malignant Lymphoma: Increased Risk of Infectious Complications , 2001, International journal of hematology.
[14] B. Dörken,et al. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors , 2001, Bone Marrow Transplantation.
[15] T. Barton,et al. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] S. Rutella,et al. Transplantation of Autologous Peripheral Blood Progenitor Cells: Impact of CD34-Cell Selection on Immunological Reconstitution , 2001, Leukemia & lymphoma.
[17] J. Friedman,et al. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation , 2000, Bone Marrow Transplantation.
[18] D. Niederwieser,et al. Phenotypic and functional lymphocyte recovery after CD34+-enriched versus non-T cell-depleted autologous peripheral blood stem cell transplantation. , 2000, Journal of hematotherapy & stem cell research.
[19] P. Chiusolo,et al. Early viral complications after autologous CD34-selected peripheral blood stem cell transplantation , 2000, Bone Marrow Transplantation.
[20] E. Thomas,et al. A review of autologous hematopoietic cell transplantation. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] H. Takamatsu,et al. Frequent viral infections and delayed CD4+ cell recovery following CD34+ cell-selected autologous peripheral blood stem cell transplantation. , 1999, International journal of hematology.
[22] H. Wandt,et al. The use of CD34+-selected PBPC after high-dose chemotherapy in breast cancer patients is associated with prolonged recovery time and increased infectious complications. , 1999, Journal of hematotherapy & stem cell research.
[23] M. Scott,et al. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis , 1999, Bone Marrow Transplantation.
[24] Y. Nakamura,et al. Cloning and characterization of ASH2L and Ash2l, human and mouse homologs of the Drosophila ash2 gene , 1999, Cytogenetic and Genome Research.
[25] Y. Kawano,et al. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience. , 1999, Haematologica.
[26] V. Bours,et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. , 1999, Haematologica.
[27] R. Salazar,et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.
[28] S. Heimfeld,et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. , 1999, Blood.
[29] B. Sautois,et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells , 1998, Transfusion.
[30] N. Schmitz,et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 , 1998, Bone Marrow Transplantation.
[31] C. Huber,et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.
[32] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[33] N. Schmitz,et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.
[34] J. Rossi,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.
[35] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[36] Riley Mb,et al. Autologous stem cell transplant: an overview. , 1994 .
[37] M. Riley,et al. Autologous stem cell transplant: an overview. , 1994, Cancer practice.
[38] F. Appelbaum,et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.